Revolution Biomanufacturing的动态

Kudo Biotechnology?and?LineaRx?present: ?WHITE PAPER – "Fast-tracking mRNA Medicines: A synthetic DNA platform to optimize mRNA production" We introduce a streamlined, flexible process for mRNA therapeutic production that eliminates traditional pDNA steps. Using cell-free enzymatic production from our partner LineaRx on the Kudo Bio platform, we enable faster, cost-effective, and scalable cGMP manufacturing of high-quality mRNA. The white paper also highlights LineaRx’s proprietary RNA polymerase, which, when combined with the linear dsDNA template, minimizes dsRNA impurities for an added advantage. Download the white paper here https://lnkd.in/g4rSvWdK

LineaRx, Inc., an Applied DNA Sciences company, and Kudo Biotechnology, introduce a new and novel platform for rapid mRNA production under GMP that utilizes a cell-free enzymatic process to replace the industry's traditional use of pDNA. Linea? DNA, a linear dsDNA template, can replace pDNA to significantly accelerate the production of high-quality mRNA therapeutics. When used in combination with a proprietary RNA polymerase (Linea? RNAP), Linea DNA further minimizes dsRNA impurities and unwanted immune responses endemic to conventional mRNA production workflows. #mRNAtherapeutics #pDNA #GMP ? Read the white paper here (registration required): https://lnkd.in/gQdctSQA

?? Exciting News from Altamira Therapeutics! ?? #Announces that our #nanoparticle-based delivery platform has successfully been tested for circular #mRNA, showing significantly higher protein expression than linear mRNA. ?? Key Highlights: - In vitro tests showed successful cell transfection. - Provisional patent application filed with the #USPTO. - #CycloPhore? platform now available for biotech and pharma companies. - Enhanced stability and lower dosing potential for therapeutic uses. Covadonga Paneda, Chief Operating Officer, highlighted the potential of circular mRNA for enhanced protein expression and stability. ClickHere: https://lnkd.in/gA9Py3NU #Biotech #Pharma #RNATechnology #Innovation #CircularRNA #DrugDevelopment #AltamiraTherapeutics #PharmaQube

What is the potential of mammalian cell lines in biologics development? ?? Mammalian cell lines are immortal cells derived from humans or other mammals and have the advantage of enabling the expression of complex molecules and the capability to produce proteins bearing human-like glycan structures, which reduce adverse immunogenic responses. Today, the field has found a frontrunner in the Chinese hamster ovary (CHO) cell line. ?? KBI Biopharma has developed significant expertise in the mammalian cell lines field and leverages the SUREtechnology platform in their cell development services. ??? Find out more about mammalian cell lines! ?? https://lnkd.in/dUFAEwE3 #mammaliancelllines #biologicsdevelopment #celllineresearch #CHOcells #SUREtechnology #proteinproduction #immunogenicresponse #biotechinnovation

NTxscribe is here!???? ? We’re thrilled to announce the full commercial availability of our benchtop RNA manufacturing system, NTxscribe, designed to accelerate innovation in personalized medicine. ? With continuous flow RNA IVT and purification, NTxscribe produces 10-50 mg of high-integrity RNA in just three hours, enabling scalable, cost-effective RNA production for researchers, biotech, and pharmaceutical innovators. ? Discover how NTxscribe is transforming biomanufacturing and making personalized therapies at scale a reality. ? Read the press release here:?https://lnkd.in/eN-8Mfhf ? #RNA #Biomanufacturing #PersonalizedMedicine #mRNA?#NTxscribe

A beautifully written article from Jérémie Parot and Luigi Calzolai et al, evaluates analytical techniques for characterizing lipid nanoparticles (LNPs) formulated with #RNA, focusing on their physical, chemical, and structural attributes. These attributes are linked to efficacy and safety, making robust characterization crucial for preclinical development and quality assurance. The article highlights several important points regarding the impact of #manufacturing on #LNP-RNA formulations. It emphasizes that losses in lipids or RNA can lead to batch-to-batch variability. Such manufacturing inconsistencies in RNA-LNP production can significantly affect the lipid and RNA content, resulting in decreased RNA delivery efficiency and reduced in vitro efficacy. Those bring to mind that selecting the right CDMO is not just beneficial but essential which ensures robust process development, precise manufacturing, and regulatory success. Corden Pharma - A Full-Service CDMO

?? ?????????????????? ???????????????????? ???????????????????? ?????? ???????? ???????????????????????????????? ???? The biopharmaceutical industry is advancing, and the demand for robust analytical methods for mRNA products is crucial. A recent study from Regeneron evaluated various capillary electrophoresis-based methods for their effectiveness in assessing the purity and stability of in vitro transcribed mRNA. This comparative analysis sheds light on the strengths and limitations of each method, guiding us toward more efficient and accurate assessments in this critical area. ?? ?????? ????????-??????????: ???SCIEX RNA 9000 Purity and Integrity Kit: Highest selectivity and resolving power, ideal for in-depth sample characterization. ???Agilent Technologies RNA 6000 Nano Kit, Revvity RNA Reagent Kit, and Agilent Technologies HS RNA Kit: Faster analysis times, suitable for high-throughput applications. ?? Balancing resolution, analysis time, and throughput is key for selecting the right analytical method. #Biopharmaceuticals #mRNA #AnalyticalChemistry #CapillaryElectrophoresis #PharmaceuticalAnalysis #LabTech #ScientificResearch Prerana Mantri, Bindiya Juneja, Steven Henderson, Evan Koufos, Youmi Moon, Daniel Dayeh, Deanna Di Grandi, Yue Fu, Kathir Muthusamy, Peter Ihnat, Nisha Palackal, Erica P.

This year’s Protein & Antibody Engineering Summit (PEGS) Europe covers a wide range of topics, including protein expression, antibody engineering, therapeutic proteins, and biopharmaceutical production. Crelux was represented at the conference with a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, affinity and kinetics determination using various biophysical techniques, and paratope and epitope mapping through structural biology. It ensures fast turnover, high quality, adherence to high scientific standards, and is tailored for maximal flexibility to streamline the drug discovery process.

Go From Batch To Continuous RNA Purification With mAb Equipment And QBD https://lnkd.in/ecjT7sJ6 - A conversation with Zoltán Kis and Adithya Nair, The University of Sheffield Overview of the proposed mRNA-based vaccines and therapeutics manufacturing process and the oligo-dT affinity purification method.

This year’s Protein & Antibody Engineering Summit (PEGS) Europe covers a wide range of topics, including protein expression, antibody engineering, therapeutic proteins, and biopharmaceutical production. Crelux was represented at the conference with a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, affinity and kinetics determination using various biophysical techniques, and paratope and epitope mapping through structural biology. It ensures fast turnover, high quality, adherence to high scientific standards, and is tailored for maximal flexibility to streamline the drug discovery process. https://lnkd.in/ewJD7NjA